X4 Pharmaceuticals (XFOR) Long-Term Debt Repayments (2017 - 2019)

X4 Pharmaceuticals has reported Long-Term Debt Repayments for 3 years, with the latest figure at $6.5 million in Q3 2019.

• For the quarter ending Q3 2019, Long-Term Debt Repayments rose 1190.8% year-over-year to $6.5 million; the trailing twelve-month figure through Dec 2020 stood at $6.5 million (down 45.46% YoY), and the FY2023 full-year result was $2.1 million, up 159.62% from the prior year.
• Long-Term Debt Repayments for Q3 2019 stood at $6.5 million, up from $4.9 million in the prior quarter.
• The five-year high for Long-Term Debt Repayments was $6.5 million in Q3 2019, with the low at -$1.8 million in Q4 2017.
• Historically, Long-Term Debt Repayments has averaged $1.4 million across 3 years, with a median of $582000.0 in 2017.
• Annual changes were most pronounced in 2018 — Long-Term Debt Repayments slipped 14.53% — and 2019, when it jumped 1190.8%.
• X4 Pharmaceuticals' Long-Term Debt Repayments stood at -$1.8 million in 2017, then jumped by 378.86% to $4.9 million in 2018, then soared by 32.25% to $6.5 million in 2019.
• The last three Long-Term Debt Repayments figures came in at $6.5 million (Q3 2019), $4.9 million (Q4 2018), and $500000.0 (Q3 2018), per Business Quant data.